A Phase 3 interventional study of mRNA-1403 and Placebo in Acute Gastroenteritis and Norovirus Acute Gastroenteritis, sponsored by ModernaTX, Inc.. Active, not recruiting at 283 sites in 7 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Gastroenteritis with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Gastroenteritis · United States.
Among the 58 studies in Gastroenteritis with a site in United States, this one has the largest enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2024, is one of 16 in phase 3, and was the 56th registered.
237 studies on the registry are indexed under Gastroenteritis; 16 are open to participants now.
Browse Gastroenteritis studies →5 of the 58 studies in Gastroenteritis with a site in United States are open now. Recruiting first, the newest first:
True Bearing Diagnostics, Inc. · Sites in United States
Ages 7+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 6–12
Paul A Breslin · Sites in United States
Ages 6 mo–5 yrs
University of Utah · Sites in United States
Ages up to 18
Aaron Etra · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Gastroenteritis studies recruiting now, 5 (38%) set no upper age limit and 8 (62%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 13 · Phase 3 20 · Phase 4 5
First in 2004; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37,864 is above the median of 136 across 164 interventional studies indexed under Gastroenteritis.
Median enrollment 87 across the 50 interventional studies, 1,000 across the 7 observational. Of the 45 that completed or were terminated, 24 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 58 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Moderna, Inc. has 2 studies filed under Gastroenteritis — fewer than ten, so there is no comparison to draw.
5 of the studies in Gastroenteritis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06592794Phase 3ModernaTX, Inc.A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis | 2027-02-15 |
| NCT06137014Paul A BreslinFortified Oral Rehydration Therapy for Pediatric Diarrhea | 2026-12 |
| NCT05471908University of UtahFollow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial | 2027-02 |
| NCT07579312True Bearing Diagnostics, Inc.Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study | 2027-04 |
| NCT07285785Bausch Health Americas, Inc.Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea | 2027-04-20 |
Add all 5 to your calendar (.ics) → With an account.
Among the 58 studies in Gastroenteritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants may have chronic medical diagnoses but should be medically stable as assessed by the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single injection of mRNA-1403 on Day 1.
Biological: mRNA-1403
Participants will receive a single injection of mRNA-1403 matching placebo (0.9% sodium chloride solution) on Day 1.
Biological: Placebo
Intramuscular (IM) injection.
0.9% sodium chloride solution by IM injection.
Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
Time frame: Day 1 up to Day 7 (7 days after study intervention)
Number of Participants with Unsolicited Adverse Events (AEs)
Time frame: Day 1 up to Day 28 (28 days after study intervention)
Number of Participants with Medically Attended Adverse Events (MAAEs)
Time frame: Day 1 through Day 181
Number of Participants with Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), and AEs Leading to Study Withdrawal
Time frame: Day 1 up to Day 546
Vaccine Efficacy (VE) of mRNA-1403 to Prevent First Occurrence of Protocol-defined Moderate or Severe AGE Associated with Vaccine Matched Genotypes
Time frame: Day 15 up to 9 months after last participant dosed
VE of mRNA-1403 to Prevent First Occurrence of Protocol-defined Severe AGE Associated with Vaccine Matched Genotypes
Time frame: Day 15 up to 9 months after last participant dosed
VE of mRNA-1403 to Prevent First Occurrence of Protocol-defined Severe Norovirus (NoV) AGE Associated with Any Genogroup I or II Norovirus (NoV) Genotype
Time frame: Day 15 up to 9 months after last participant dosed
VE of mRNA-1403 to Prevent First Occurrence of Protocol-defined Moderate or Severe AGE Associated with Any Genogroup I or II NoV Genotype
Time frame: Day 15 up to 9 months after last participant dosed
VE of mRNA-1403 to Prevent First Occurrence of Protocol-defined AGE of Any Severity Associated with Vaccine Matched NoV Genotypes
Time frame: Day 15 up to 9 months after last participant dosed
VE of mRNA-1403 to Prevent Any Occurrence of Medically Attended AGE Associated with Vaccine Matched NoV Genotypes, as well as any Genogroup I or II NoV Genotype
Time frame: Day 15 up to Day 546
VE of mRNA-1403 to Prevent Any Occurrence of AGE Hospitalizations Associated With Vaccine Matched NoV Genotypes, as well as any Genogroup I or II NoV Genotype
Time frame: Day 15 up to Day 546
VE of mRNA-1403 to Prevent Any Occurrence of Protocol-defined Moderate or Severe AGE Associated with Vaccine Matched Genotypes
Time frame: Day 15 up to Day 546
VE of mRNA-1403 to Prevent Any Occurrence of Protocol-defined AGE of Any Severity Associated with Any Genogroup I or II NoV Genotype
Time frame: Day 15 up to Day 546
Geometric Mean Titer (GMT) of Histo-blood Group Antigen (HBGA)-blocking Antibodies Titers Against Vaccine Matched Genotypes
Time frame: Day 1 and Day 29
Geometric Mean Fold Rise (GMFR) of HBGA-blocking Antibodies Titers Against Vaccine Matched Genotypes
Time frame: Day 1 and Day 29
Percentage of Participants with Seroresponse Based on HBGA-blocking Antibody Titer
Time frame: Day 29
GMT of Binding Antibody (bAb) Against Vaccine-matched NoV Genotypes
Time frame: Day 1 and Day 29
GMFR of bAb Titers
Time frame: Day 1 and Day 29
Percentage of Participants with Seroresponse Based on bAb Titer
Time frame: Day 29
VE of mRNA-1403 to Prevent First Occurrence of Protocol-Defined Moderate or Severe AGE Associated with Vaccine-Matched NoV Genotypes Up to 12 Months
Time frame: Day 15 up to 12 months postdose
VE of mRNA-1403 to Prevent First Occurrence of Protocol-Defined Moderate or Severe AGE Associated with Vaccine-Matched NoV Genotypes Up to 18 Months
Time frame: Day 15 up to 18 months postdose
Showing the first 100 of 283 sites across 7 countries. Choose a country and city above to see the rest.
Started Sep 2024 (actual). Primary completion is estimated for Feb 2027, 28 months after the start.
Of 21 industry-sponsored phase 3 interventional studies under Gastroenteritis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 28 months is above that.
Counting every sponsor, half of 25 studies reached it within 19 months; a quarter within 11 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.